This segment focuses on the research, development, and commercialization of novel treatments for gastrointestinal (GI) diseases. The primary focus is on vonoprazan, a potassium-competitive acid blocker (P-CAB), and its applications in treating erosive gastroesophageal reflux disease (GERD) and Helicobacter pylori (H. pylori) infection. Research and development activities include Phase III clinical trials, formulation development, and exploring combination therapies. Technologies employed include advanced drug delivery systems and clinical trial methodologies. The segment aims to improve patient outcomes by providing effective and convenient treatment options for common GI disorders. Market positioning is based on the innovative mechanism of action of vonoprazan, offering a potential advantage over existing proton pump inhibitors (PPIs). Future opportunities include expanding the label for vonoprazan and developing new GI therapies. Regulatory aspects involve obtaining FDA approvals and maintaining intellectual property protection. Partnerships with Evonik for manufacturing and Takeda/Frazier for initial collaboration are key.